Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies.

In SLE, rituximab reduced triglycerides and resultant atherogenic index of plasma values, likely associated with improvement in disease activity, although reductions in total cholesterol and LDL-C did not reach statistical significance and HDL levels remained stable ( 143 ).

also in 111,027 other papers